Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.39 AUD | +0.13% | +0.07% | +52.68% |
05:34am | Telix Pharmaceuticals Concludes Proof-of-Concept Study of Advanced Prostate Cancer Drug | MT |
May. 20 | Telix Pharmaceuticals Files Registration Statement for Nasdaq IPO | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+52.68% | 3.43B | |
+41.98% | 54.04B | |
+43.57% | 41.96B | |
-1.13% | 41.92B | |
-7.59% | 28.35B | |
+12.22% | 26.35B | |
-22.44% | 19B | |
+7.84% | 13B | |
+29.16% | 12.28B | |
+25.14% | 12.19B |
- Stock Market
- Equities
- TLX Stock
- News Telix Pharmaceuticals Limited
- Transcript : Telix Pharmaceuticals Limited, 2022 Earnings Call, Feb 27, 2023